For Dr Jean-Luc Dourson, founder and director of BioneXt LAB, medical biology is more than ever a sector with a future. “Medical analysis is a key element of the healthcare process, as the medical biologist and laboratory analysis contribute to the disease diagnosis and the treatment monitoring in nearly 70% of the cases.”
Private medical biology is nonetheless a highly competitive sector under pressure – particularly as regards pricing. New regulations have led to a significant drop in the number of prescriptions. “Even if the nomenclature of analysis laboratories had to be revised because it had become totally outdated in structural and medico-technical terms, it is so complex that it is nearly impossible for a doctor to know whether the analyses he prescribes will be reimbursed by the health insurance scheme,” Dr Dourson continues. Apart from the fact that medical analysis laboratories have no alternative but to invoice the patient for the part not reimbursed by the CNS [Luxembourgish health service] under the third-party payment system, the new prescription rules are also detrimental to the doctor’s freedom of therapeutic choice.
The Luxembourgish laboratory BioneXt LAB relies on three strategic lines of approach to boost its growth: digitization, service harmonization and virtual reality.
“Our laboratory processes deal with highly sensitive health data. With EBRC we have a reliable partner who understands the specific challenges of our business,” says Dr Jean-Luc Dourson, founder and director of BioneXt LAB.